Argos Therapeutics Priced, Nasdaq: ARGS
Developing immunotherapies for the treatment of renal cell carcinoma and HIV.
Industry: Health Care
First Day Return: 0.0%
Industry: Health Care
ARGS
Developing immunotherapies for the treatment of renal cell carcinoma and HIV.
| IPO Data | |
|---|---|
| IPO File Date | 12/30/2013 |
| Offer Price | $8.00 |
| Price Range $13.00 - $15.00 | |
| Offer Shares (mm) | 5.6 |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/06/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Durham, NC, United States |
| Founded | 1997 |
| Employees at IPO | 94 |
| Website www.argostherapeutics.com | |
IPO News for Argos Therapeutics
Argos Therapeutics (ARGS) Performance
